Human trial
VIP primary study · PMID 36044317
196 hospitalized patients with critical COVID-19 respiratory failure.
Reported findings. No positive effect established on the stated primary outcome.
Nonresponse. The prespecified primary outcome did not reach statistical significance.
Harms. Unknown in reviewed excerpt; absence of mention is not safety evidence.
Limits. Selected secondary findings cannot turn a negative primary endpoint into proven efficacy. The IV trial does not establish nasal-spray wellness effects.
Preparation: Source preparation; commercial equivalence unverified. Route: Unknown in reviewed excerpt; do not infer.
Read original source ↗Editorial review 2026-10-09. Clinician review pending.